Question | Discussion | References | CME Credit

Case 5: References

  1. Schambelan M, Benson CA, Carr A, et al; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31:257-75.
    [The following link will open in a new window. PubMed Abstract]
  2. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S96-S100.
    [The following link will open in a new window. PubMed Abstract]
  3. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-32.
    [The following link will open in a new window. PubMed Abstract]
  4. Boubaker K, Flepp M, Sudre P, et al A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33:1931-7.
    [The following link will open in a new window. PubMed Abstract]
  5. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-9.
    [The following link will open in a new window. PubMed Abstract]
  6. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-1.
    [The following link will open in a new window. PubMed Abstract]
  7. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis. 2003;36:1324-8.
    [The following link will open in a new window. PubMed Abstract]
  8. Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 2003;79:340-4.
    [The following link will open in a new window. PubMed Abstract]
  9. Gerard Y, Maulin L, Yazdanpanah Y,et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS. 2000;14:2723-30.
    [The following link will open in a new window. PubMed Abstract]
  10. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77:158-73.
    [The following link will open in a new window. PubMed Abstract]
  11. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-44.
    [The following link will open in a new window. PubMed Abstract]
  12. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000;13:5-11.
    [The following link will open in a new window. PubMed Abstract]
  13. Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen. 2006;47:Jun 6 [Epub ahead of print].
    [The following link will open in a new window. PubMed Abstract]
  14. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-20.
    [The following link will open in a new window. PubMed Abstract]
  15. Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, Nakamura T, Iwamoto A. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol. 2003;70:497-505.
    [The following link will open in a new window. PubMed Abstract]
  16. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716-23.
    [The following link will open in a new window. PubMed Abstract]
  17. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38:2743-9.
    [The following link will open in a new window. PubMed Abstract]
  18. Mallon PW, Unemori P, Sedwell R, et al. In Vivo, Nucleoside Reverse-Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA. J Infect Dis. 2005;191:1686-96.
    [The following link will open in a new window. PubMed Abstract]
  19. Chen YD, Varasteh BB, Reaven GM. Plasma lactate concentration in obesity and type 2 diabetes. Diabete Metab. 1993;19:348-54.
    [The following link will open in a new window. PubMed Abstract]
  20. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-6.
    [The following link will open in a new window. PubMed Abstract]
  21. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet. 1998;352:291-2.
    [The following link will open in a new window. PubMed Abstract]
  22. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS. 1997;11:1294-6.
    [The following link will open in a new window. PubMed Abstract]
  23. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol. 1999;16:733-5.
    [The following link will open in a new window. PubMed Abstract]
  24. For the ESS40010 (TARHEEL) Study Team. Lack of Recurrence of hyperlactatemia in HIV-Infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2004;36:935-42.
    [The following link will open in a new window. PubMed Abstract]
  25. Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS. 2003;17:2495-9.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 5 Question | Back to Discussion]

CME Credit | Back to Top